# Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

> **NCT05785208** · PHASE4 · UNKNOWN · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 122 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT05785208
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-28
- **Primary completion:** 2024-02-28
- **Final completion:** 2025-10-31
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05785208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05785208, "Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05785208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*